Clinical trial
Low-intensity Chemotherapy Combined With Targeted-Immunotherapy for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Prospective Clinical Cohort Study
NCT07493161 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Low-intensity Chemotherapy Combined With Targeted-Immunotherapy for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Prospective Clinical Cohort Study
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- April 10, 2026
- Completion date
- March 30, 2030
- Enrollment
- 110 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
ph+ all